Stockwatch: Don't tell, hope no-one asks
This article was originally published in Scrip
Executive Summary
The British legal system, respected and emulated around the world, is an adversarial one where the defence and the prosecution face off in a battle of words. I am starting to think that the battle for investors' money is also adversarial with the companies putting out statements that should be interrogated and challenged. When these statements aren't challenged, investors can become the collateral damage.
You may also be interested in...
Stock Watch: Protocol Changes Preface Poor Trial Outcomes
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.